| Last follow-up on canakinumab | Last follow-up on anakinra | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Patient number | Dose, mg (mg/Kg)/frequency | CRP, mg/dl | SAA, mg/l | Clinical assessment | Response | Dose. mg (mg/kg)/frequency | CRP, mg/dl | SAA mg/l | Clinical assessment | Response |
11 | 300 (4.30)/5 wks | 1.17 | 29.9 | mild | partial | 75 (1.30)/day | 0.61 | 25.0 | absent | partial |
21 | 150 (4.00)/6 wks | 1.18 | ND | moderate | inadequate | 75 (2.00)/day | neg | 18.0 | absent | partial |
31 | 300 (5.90)/6 wks | 2.67 | 18.1 | absent | partial | 100 (1.80)/day | 0.47 | 7.50 | absent | partial |
41 | 150 (2.80)/6 wks | neg | neg | absent | complete | 100 (2.00)/day | neg | neg | minimal | complete |
52 | 78 (2.00)/8 wks | neg | neg | absent | complete | 55 (2.00)/day | neg | neg | minimal | complete |
62 | 300 (3.75)/7 wks | 0.57 | 6.5 | absent | partial | 100 (1.16)/day | 0.63 | neg | mild | partial |
71 | 300 (3.70)/4 wks | 1.20 | 64.0 | mild | partial | 100 (1.30)/day | 0.73 | neg | absent | partial |
82 | 150 (2.30)/6 wks | neg | neg | absent | complete | ND | ND | ND | ND | ND |
92 | 150 (2.40)/8 wks | neg | neg | absent | complete | 50 (1.00)/day | neg | neg | absent | complete |
102 | 100 (2.00)/8 wks | neg | neg | absent | complete | 20 (0.66)/day | neg | neg | absent | complete |
111 | 60 (2.00)/7 wks | neg | neg | absent | complete | 23 (1.00)/day | neg | 13.2 | mild | partial |
121 | 150 (2.00)/8 wks | neg | neg | absent | complete | 55 (1.00)/day | neg | neg | absent | complete |
132 | 78 (2.00)/10 wks | neg | neg | absent | complete | 38 (1.00)/day | neg | neg | absent | complete |